verapamil and Diabetes Mellitus, Type 2 studies

Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

Excerpt	Relevance	Reference
"The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment."	9.15	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. ( Bossi, A; Chiurchiu, C; Cravedi, P; Ene-Iordache, B; Fassi, A; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, A; Motterlini, N; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2011)
"Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients."	9.11	The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004)
"To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure."	9.06	Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. ( Anderson, NM; Cruickshank, JK; Jepson, E; Wadsworth, J; Young, SM, 1988)
" Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation."	8.31	Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. ( Haque, OI; Hussain, S; Mahar, S; Sloane, P, 2023)
"Angiotensin II (Ang II) is able to induce free radical generation in neutrophils, which is more elevated in neutrophils of patients with hypercholesterolemia (HC)."	7.73	The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome. ( Balogh, Z; Fóris, G; Fülöp, P; Kassai, A; Kosztáczky, B; Paragh, G; Seres, I; Varga, Z, 2006)
"To report the clinical characteristics of liver failure developing in a patient receiving rosiglitazone."	7.70	Hepatic failure in a patient taking rosiglitazone. ( Diamond, RH; Forman, LM; Simmons, DA, 2000)
"The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients."	6.76	Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. ( Castro-Serna, D; Escalante-Acosta, BA; Rodríguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2011)
"In hypertensive patients with type 2 diabetes mellitus in the BENEDICT (BErgamo NEphrologic DIabetes Complications Trial), trandolapril/verapamil SR prolonged the time to the onset of persistent microalbuminuria compared with placebo, as did trandolapril monotherapy."	6.43	Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005)
" We performed a randomized-controlled trial of lisinopril alone (an ACEI) or in combination with verapamil (a CCB) as a therapy for DN in type 2 diabetes mellitus (T2DM) patients with hypertension (HTN) and urinary albumin creatinine ratio (UACR) (30-300 mg/g) also to evaluate their effect on UACR, the angiogenic proteins: Angiopoietin 2 (Ang-2) and Endostatin (EST)."	5.41	Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy: A Randomized Trial. ( Abdel-Aleem, E; El-Mesallamy, HO; Salem, M; Sallam, AM, 2021)
"The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension."	5.20	The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015)
"The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment."	5.15	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. ( Bossi, A; Chiurchiu, C; Cravedi, P; Ene-Iordache, B; Fassi, A; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, A; Motterlini, N; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2011)
" We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks."	5.13	Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. ( Bacher, P; Champion, A; Fakouhi, K; Tian, M; Toto, RD, 2008)
"Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients."	5.11	The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. ( Arceo-Navarro, A; Gomez-Harper, CT; Lozano-Nuevo, JJ; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2004)
"In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandolapril alone decreased the incidence of microalbuminuria to a similar extent."	5.11	Preventing microalbuminuria in type 2 diabetes. ( Arnoldi, F; Bossi, A; Bruno, S; Brusegan, V; Dodesini, AR; Ene-Iordache, B; Fassi, A; Ganeva, M; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, AP; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2004)
" Therefore, the triad of metabolic neutrality with antihypertensive and antiproteinuric efficacy supports combined verapamil-trandolapril as a potentially valuable therapy for hypertension accompanying diabetes mellitus."	5.08	Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. ( Boehlen, L; Buechel, P; Lerch, M; Papiri, M; Risen, W; Schneider, M; Shaw, S; Weidmann, P, 1996)
"The present randomized, open label, parallel group designed study tests the hypothesis that, at similar levels of blood pressure, the combination of an ACE inhibitor, trandolapril (T) with the non-DHPCA, verapamil (V) produces a greater reduction in proteinuria over either agent alone at one year."	5.08	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. ( Bakris, GL; DeQuattro, V; McMahon, FG; Weir, MR, 1998)
"The effects of one month's treatment with each of nifedipine, verapamil, diltiazem, propranolol and placebo, given in random order, on fasting plasma glucose, haemoglobin Alc, serum fructosamine, immunoreactive insulin, cholesterol, and triglyceride were studied in a group of 19 patients with hypertension and non-insulin dependent diabetes mellitus."	5.06	The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. ( Chellingsworth, MC; Kendall, MJ; Pasi, J; Singh, BM; Wright, AD, 1989)
"To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure."	5.06	Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. ( Anderson, NM; Cruickshank, JK; Jepson, E; Wadsworth, J; Young, SM, 1988)
"SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism."	4.81	[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002)
" Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation."	4.31	Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. ( Haque, OI; Hussain, S; Mahar, S; Sloane, P, 2023)
"7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients."	3.75	INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009)
"Angiotensin II (Ang II) is able to induce free radical generation in neutrophils, which is more elevated in neutrophils of patients with hypercholesterolemia (HC)."	3.73	The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome. ( Balogh, Z; Fóris, G; Fülöp, P; Kassai, A; Kosztáczky, B; Paragh, G; Seres, I; Varga, Z, 2006)
"To report the clinical characteristics of liver failure developing in a patient receiving rosiglitazone."	3.70	Hepatic failure in a patient taking rosiglitazone. ( Diamond, RH; Forman, LM; Simmons, DA, 2000)
"The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients."	2.76	Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. ( Castro-Serna, D; Escalante-Acosta, BA; Rodríguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2011)
" This may explain some of the beneficial effects of this fixed dosed combination that are non-related to its antihypertensive effects."	2.73	The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. ( Escalante-Acosta, BA; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2008)
"Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy."	2.71	The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. ( , 2003)
"Fifteen male patients with type 2 diabetes (aged 54+/-4 years, mean+/-SD) were entered into a randomised, cross-over design study, examining the effect of a 30-min intra-femoral infusion of SNP on leg glucose uptake."	2.71	Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes. ( Drew, BG; Duffy, SJ; Formosa, MF; Henstridge, DC; Kingwell, BA; McConell, GK, 2005)
"Microalbuminuria is an early marker of diabetic nephropathy, and its prevention can be considered to be the primary prevention of diabetic nephropathy."	2.69	Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. ( Remuzzi, G; Ruggenenti, P, 1998)
"A total of 898 men and women with type 2 diabetes mellitus and hypertension, receiving antihypertensive treatment with one single drug and whose BP was > 140 and/or 90 mmHg."	2.69	Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. ( Coca, A; de la Cámara, AG; de la Figuera, M; de la Sierra, A; Fernández, R; Garrido, J; Luque-Otero, M; Moreno, E; Ruilope, LM, 1999)
" Forearm blood flow dose-response curves were determined for each drug before and during concomitant intraarterial administration of vitamin C (24 mg/min)."	2.68	Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. ( Boles, KS; Creager, MA; Creager, SJ; Ganz, P; Timimi, FK; Ting, HH, 1996)
"Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect."	2.68	Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. ( Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N, 1997)
"Renal hemodynamics, albuminuria and metabolic parameters were evaluated for a period of one year."	2.67	Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. ( Bakris, GL; Barnhill, BW; Sadler, R, 1992)
"In hypertensive patients with NIDDM, a diuretic-free therapy based on the Ca2+ antagonist verapamil and/or the ACE inhibitor enalapril can effectively decrease blood pressure without adversely affecting carbohydrate and lipid metabolism."	2.67	Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. ( Beretta-Piccoli, C; Ferrari, P; Ferrier, C; Keller, U; Riesen, WF; Weidmann, P, 1991)
"Verapamil has previously been found to inhibit insulin release from pancreatic beta-cells in laboratory animals."	2.65	Influence of verapamil on glucose tolerance. ( Andersson, DE; Röjdmark, S, 1984)
"Mycophenolic acid was detected in all cats."	2.61	( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Prevalence of hypertension is much higher among diabetic than non-diabetic patients, and the hypertensive patient is more likely to develop type 2 diabetes."	2.44	Trandolapril/verapamil combination in hypertensive diabetic patients. ( García Donaire, JA; Ruilope, LM, 2007)
"In hypertensive patients with type 2 diabetes mellitus in the BENEDICT (BErgamo NEphrologic DIabetes Complications Trial), trandolapril/verapamil SR prolonged the time to the onset of persistent microalbuminuria compared with placebo, as did trandolapril monotherapy."	2.43	Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005)
"Verapamil treatment had no significant effect on blood glucose, but blood glucose tended to decline with the increase of verapamil-treated time and dose."	1.72	Improved fatigue properties, bone microstructure and blood glucose in type 2 diabetic rats with verapamil treatment. ( Gong, H; Hu, X; Jia, S; Li, J; Wu, X, 2022)
"Verapamil was mainly used to treat hypertension, cardiovascular disease, inflammation and improve blood glucose in patients with diabetes, but its effects on bone mass, microstructure and mechanical properties were unclear."	1.72	Effect of verapamil on bone mass, microstructure and mechanical properties in type 2 diabetes mellitus rats. ( Cen, H; Gong, H; Hu, X; Li, C; Shi, P; Wu, X, 2022)
" Forearm blood flow was determined by venous occlusion plethysmography, and dose-response curves were generated for each agent."	1.29	Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. ( Creager, MA; Cusco, JA; Johnstone, MT; Roddy, MA; Williams, SB, 1996)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (7.69)	18.7374
1990's	14 (21.54)	18.2507
2000's	28 (43.08)	29.6817
2010's	11 (16.92)	24.3611
2020's	7 (10.77)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone[NCT03317028]	Phase 2	201 participants (Actual)	Interventional	2017-10-10	Completed
A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151]	Phase 2	138 participants (Anticipated)	Interventional	2021-02-08	Recruiting
INternational VErapamil SR Trandolapril STudy[NCT00133692]	Phase 4	22,000 participants	Interventional	1997-09-30	Completed
Qianyangyuyin Formula Prevent and Treat for Early Renal Injury in Hypertensive Patients[NCT04078711]	Phase 2/Phase 3	520 participants (Anticipated)	Interventional	2019-09-10	Not yet recruiting
A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014]	Phase 4	1,204 participants (Actual)	Interventional	1997-03-31	Completed
The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study[NCT04092439]		18 participants (Actual)	Interventional	2019-09-12	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P	2019
Treatments for diabetes mellitus type II: New perspectives regarding the possible role of calcium and cAMP interaction. European journal of pharmacology, 2018, Jul-05, Volume: 830 Topics: Adjuvants, Pharmaceutic; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Cyclic	2018
The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review. Acta diabetologica, 2020, Volume: 57, Issue:2 Topics: B-Lymphocytes; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fastin	2020
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito	2002
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs, 2005, Volume: 65, Issue:13 Topics: Adult; Aged; Antihypertensive Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug C	2005
Trandolapril/verapamil combination in hypertensive diabetic patients. Vascular health and risk management, 2007, Volume: 3, Issue:1 Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Drug T	2007

Article	Year
A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes. The Journal of clinical endocrinology and metabolism, 2022, 09-28, Volume: 107, Issue:10 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H	2022
Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy: A Randomized Trial. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2021, Volume: 53, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic	2021
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:3 Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatinine; Diabetes Mellit	2015
The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clinical and experimental hypertension (New York, N.Y. : 1993), 2008, Volume: 30, Issue:7 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; C	2008
Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:10 Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be	2008
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of hypertension, 2011, Volume: 29, Issue:2 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe	2011
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of hypertension, 2011, Volume: 29, Issue:2 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe	2011
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of hypertension, 2011, Volume: 29, Issue:2 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe	2011
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of hypertension, 2011, Volume: 29, Issue:2 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe	2011
Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. Therapeutic advances in cardiovascular disease, 2011, Volume: 5, Issue:4 Topics: Adiponectin; Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Calcium Channel Bl	2011
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. Journal of the American Society of Nephrology : JASN, 2012, Volume: 23, Issue:10 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Cardiotonic Agents; Cardiov	2012
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. American journal of hypertension, 2003, Volume: 16, Issue:5 Pt 1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor	2003
The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Controlled clinical trials, 2003, Volume: 24, Issue:4 Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium	2003
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. Journal of hypertension, 2004, Volume: 22, Issue:1 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure;	2004
The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes care, 2004, Volume: 27, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Body Weight; Calcium Channe	2004
Preventing microalbuminuria in type 2 diabetes. The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19 Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium	2004
BENEDICT in the treatment of hypertension. Current hypertension reports, 2005, Volume: 7, Issue:2 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Calcium Channe	2005
Effects of the nitric oxide donor, sodium nitroprusside, on resting leg glucose uptake in patients with type 2 diabetes. Diabetologia, 2005, Volume: 48, Issue:12 Topics: Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type	2005
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc	2006
[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension]. Kardiologiia, 2007, Volume: 47, Issue:11 Topics: Adult; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relation	2007
Influence of verapamil on glucose tolerance. Acta medica Scandinavica. Supplementum, 1984, Volume: 681 Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Toleran	1984
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. The Journal of clinical investigation, 1996, Jan-01, Volume: 97, Issue:1 Topics: Adult; Antioxidants; Ascorbic Acid; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans	1996
Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. Journal of hypertension, 1996, Volume: 14, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Carbohydrate Metabolism; Chlortha	1996
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension (Dallas, Tex. : 1979), 1997, Volume: 29, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers;	1997
Primary prevention of renal failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1998, Volume: 16, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabete	1998
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney international, 1998, Volume: 54, Issue:4 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diabetes M	1998
Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. Journal of hypertension, 1999, Volume: 17, Issue:12 Pt 2 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Attitude to Health; Blood P	1999
Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. Journal of human hypertension, 2001, Volume: 15, Issue:12 Topics: Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-	2001
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2002, Volume: 22, Issue:2 Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih	2002
The effect of sustained release verapamil on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Drugs, 1992, Volume: 44 Suppl 1 Topics: Adult; Aged; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Male;	1992
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney international, 1992, Volume: 41, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations;	1992
Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. European journal of clinical pharmacology, 1991, Volume: 41, Issue:5 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Male; Middle Aged; V	1991
Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes care, 1991, Volume: 14, Issue:10 Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Fema	1991
The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. Journal of human hypertension, 1989, Volume: 3, Issue:1 Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Diltiazem; Female; Fruc	1989
Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. BMJ (Clinical research ed.), 1988, Nov-05, Volume: 297, Issue:6657 Topics: Aged; Albuminuria; Black or African American; Clinical Trials as Topic; Diabetes Mellitus, Type 2; D	1988

Article	Year
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. Journal of medicinal chemistry, 2010, Apr-22, Volume: 53, Issue:8 Topics: Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; CHO Cell	2010
Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. Journal of medicinal chemistry, 2016, Mar-24, Volume: 59, Issue:6 Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Discovery; Glucose Tolerance Test; Hypoglyce	2016
Clinically Significant Bradycardia and Hypotension Following Consumption of Betel Leaf in a Patient Treated for Chronic Atrial Fibrillation. Journal of pharmacy practice, 2023, Volume: 36, Issue:2 Topics: Aged; Atrial Fibrillation; Bradycardia; Diabetes Mellitus, Type 2; Female; Humans; Hypotension; Meto	2023
Effect of verapamil on bone mass, microstructure and mechanical properties in type 2 diabetes mellitus rats. BMC musculoskeletal disorders, 2022, Apr-18, Volume: 23, Issue:1 Topics: Animals; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Experimental; Diabetes Mell	2022
Improved fatigue properties, bone microstructure and blood glucose in type 2 diabetic rats with verapamil treatment. Clinical biomechanics (Bristol, Avon), 2022, Volume: 98 Topics: Animals; Blood Glucose; Bone Density; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fr	2022
Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. BMJ case reports, 2023, Jan-13, Volume: 16, Issue:1 Topics: Bradycardia; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hypertens	2023
Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus. The Journal of clinical endocrinology and metabolism, 2017, 07-01, Volume: 102, Issue:7 Topics: Administration, Oral; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relation	2017
Beta cell preservation in patients with type 1 diabetes. Nature medicine, 2018, Volume: 24, Issue:8 Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Insulin-Secreting Cells; Verapa	2018
Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 296, Issue:5 Topics: Animals; Apoptosis; Calcium Channel Blockers; Carrier Proteins; Caspase 3; Cell Line; Cell Survival;	2009
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:11 Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro	2009
Effect of fluvastatin, lovastatin, nifedipine and verapamil on the systemic exposure of nateglinide in rabbits. Biopharmaceutics & drug disposition, 2010, Volume: 31, Issue:8-9 Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Cyclohexanes; Cy	2010
[Heart rate variability in patients with hypertension and type 2 diabetes treated with long acting calcium antagonists]. Kardiologiia, 2003, Volume: 43, Issue:5 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bl	2003
[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus]. Klinicheskaia meditsina, 2005, Volume: 83, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Glucose; Calcium Channel Blockers; Clinical Trial	2005
[Prevention of microalbuminuria in type 2 diabetes. BENEDICT study]. Der Internist, 2006, Volume: 47, Issue:2 Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium	2006
Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams? Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Bloc	2006
The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome. The Journal of membrane biology, 2006, Volume: 214, Issue:2 Topics: Adult; Angiotensin I; Angiotensin II; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type	2006
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology, 1996, Mar-01, Volume: 27, Issue:3 Topics: Adult; Analysis of Variance; Blood Flow Velocity; Case-Control Studies; Constriction, Pathologic; Di	1996
The riddle of formycin A insulinotropic action. Biochemical and molecular medicine, 1996, Volume: 57, Issue:1 Topics: Adenosine; Animals; Calcium; Diabetes Mellitus, Type 2; Diazoxide; Female; Formycins; Glucose; Glybu	1996
Augmented Ca2+ influx is involved in the mechanism of enhanced proliferation of cultured vascular smooth muscle cells from spontaneously diabetic Goto-Kakizaki rats. Atherosclerosis, 1997, Volume: 131, Issue:2 Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e	1997
[Obesity in the service of Justice. New drug-combination leads to protection of the kidney]. Fortschritte der Medizin, 1997, Nov-20, Volume: 115, Issue:32 Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Diabet	1997
Hepatic failure in a patient taking rosiglitazone. Annals of internal medicine, 2000, Jan-18, Volume: 132, Issue:2 Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Hum	2000
[ACE inhibitor and calcium channel blocker in a fixed combination. Lowering blood pressure in diabetic patients]. MMW Fortschritte der Medizin, 2000, Jul-27, Volume: 142, Issue:30 Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypertension; Indoles	2000
[Accomplishing 2 goals at once. Nephropathy and cardiac risk]. MMW Fortschritte der Medizin, 2000, Jul-27, Volume: 142, Issue:30 Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hyp	2000
[Diabetic nephropathy with nephrotic syndrome--apropos of 2 cases. Advantages of combined conversion enzyme inhibitor and non-dihydropyridine calcium antagonist treatment]. Praxis, 2000, Aug-24, Volume: 89, Issue:34 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2;	2000
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care]. Praxis, 2002, May-08, Volume: 91, Issue:19 Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Ty	2002
Influence of verapamil on human glucose tolerance. The American journal of cardiology, 1986, Feb-26, Volume: 57, Issue:7 Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Female; Gluco	1986
Plasma lipid profile in verapamil-treated hypertensive patients. International journal of clinical pharmacology, therapy, and toxicology, 1987, Volume: 25, Issue:9 Topics: Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypertension; Lipids; Lipoproteins, HDL; Lipoprotein	1987

verapamil and Diabetes Mellitus, Type 2

Research Excerpts

Research

Studies (65)

Authors

Clinical Trials (6)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Kakinuma, H	1
Oi, T	1
Hashimoto-Tsuchiya, Y	1
Arai, M	1
Kawakita, Y	1
Fukasawa, Y	1
Iida, I	1
Hagima, N	1
Takeuchi, H	1
Chino, Y	1
Asami, J	1
Okumura-Kitajima, L	1
Io, F	1
Yamamoto, D	1
Miyata, N	1
Takahashi, T	1
Uchida, S	1
Yamamoto, K	1
Hansen, SV	1
Christiansen, E	1
Urban, C	1
Hudson, BD	1
Stocker, CJ	1
Due-Hansen, ME	1
Wargent, ET	1
Shimpukade, B	1
Almeida, R	1
Ejsing, CS	1
Cawthorne, MA	1
Kassack, MU	1
Milligan, G	1
Ulven, T	1
Bannister, BE	1
Parry, DR	1
Pouliot, JD	1
Wu, X	3
Gong, H	2
Hu, X	3
Shi, P	1
Cen, H	1
Li, C	3
Jia, S	1
Li, J	6
Wang, CY	1
Huang, KC	2
Lu, CW	1
Chu, CH	1
Huang, CN	1
Chen, HS	1
Lee, IT	1
Chen, JF	1
Chen, CC	1
Chen, CS	1
Hsieh, CH	1
Tien, KJ	1
Chien, HY	1
Huang, YY	1
Hsu, JP	1
Shane, GT	1
Chang, AC	1
Wu, YC	1
Sheu, WH	1
Haque, OI	1
Mahar, S	1
Hussain, S	1
Sloane, P	1
Bobenko, AI	1
Heller, S	1
Schmitt, N	1
Cherdtrakulkiat, R	1
Lawung, R	1
Nabu, S	1
Tantimavanich, S	1
Sinthupoom, N	1
Prachayasittikul, S	1
Prachayasittikul, V	1
Zhang, B	1
Wu, C	1
Zhang, Z	2
Yan, K	1
Li, Y	4
Li, L	3
Zheng, C	1
Xiao, Y	1
He, D	1
Zhao, F	1
Su, JF	1
Lun, SM	1
Hou, YJ	1
Duan, LJ	1
Wang, NC	1
Shen, FF	1
Zhang, YW	1
Gao, ZW	1
Du, XJ	1
Zhou, FY	1
Yin, Z	1
Zhu, J	2
Yan, D	1
Lou, H	1
Yu, H	1
Feng, C	1
Wang, Z	1
Wang, Y	4
Li, Z	2
Shen, Y	1
Hu, D	1
Chen, H	1
Duan, Y	1
Zhi, D	1
Zou, M	2
Zhao, Z	1
Zhang, X	2
Yang, X	2
Zhang, J	2
Wang, H	1
Popović, KJ	1
Popović, DJ	1
Miljković, D	1
Lalošević, D	1
Čapo, I	1
Popović, JK	1
Liu, M	1
Song, H	2
Xing, Z	1
Lu, G	1
Chen, D	1
Valentini, AM	1
Di Pinto, F	1
Coletta, S	1
Guerra, V	1
Armentano, R	1
Caruso, ML	1
Gong, J	1
Wang, N	1
Bian, L	1
Wang, M	1
Ye, M	1
Wen, N	1
Fu, M	1
Fan, W	1
Meng, Y	1
Dong, G	1
Lin, XH	1
Liu, HH	1
Gao, DM	1
Cui, JF	1
Ren, ZG	1
Chen, RX	1
Önal, B	1
Özen, D	1
Demir, B	1
Akkan, AG	1
Özyazgan, S	1
Payette, G	1
Geoffroy, V	1
Martineau, C	1
Villemur, R	1
Jameel, T	1
Baig, M	1
Gazzaz, ZJ	1
Tashkandi, JM	1
Al Alhareth, NS	1
Khan, SA	1
Butt, NS	1
Wang, J	2
Geng, Y	1
Zhang, Y	3
Wang, X	2
Liu, J	2
Basit, A	1
Miao, T	1
Liu, W	1
Jiang, W	1
Yu, ZY	1
Wu, L	2
Qu, B	1
Sun, JX	1
Cai, AL	1
Xie, LM	1
Groeneveld, J	1
Ho, SL	1
Mackensen, A	1
Mohtadi, M	1
Laepple, T	1
Genovesi, S	1
Nava, E	1
Bartolucci, C	1
Severi, S	1
Vincenti, A	1
Contaldo, G	1
Bigatti, G	1
Ciurlino, D	1
Bertoli, SV	1
Slovak, JE	1
Hwang, JK	1
Rivera, SM	1
Villarino, NF	1
Li, S	1
Cao, G	1
Ling, M	1
Ji, J	1
Zhao, D	1
Sha, Y	1
Gao, X	1
Liang, C	2
Guo, Q	1
Zhou, C	1
Ma, Z	1
Xu, J	1
Wang, C	1
Zhao, W	1
Xia, X	1
Jiang, Y	1
Peng, J	1
Jia, Z	1
Li, F	1
Chen, X	2
Mo, J	1
Zhang, S	2
Li, X	1
Huang, T	1
Zhu, Q	1
Wang, S	1
Ge, RS	1
Fortunato, G	1
Lin, J	2
Agarwal, PK	1
Kohen, A	1
Singh, P	1
Cheatum, CM	1
Zhu, D	1
Hayman, A	1
Kebede, B	1
Stewart, I	1
Chen, G	1
Frew, R	1
Guo, X	1
Gong, Q	1
Borowiec, J	1
Han, S	1
Zhang, M	1
Willis, M	1
Kreouzis, T	1
Yu, K	1
Chirvony, VS	1
Sekerbayev, KS	1
Pérez-Del-Rey, D	1
Martínez-Pastor, JP	1
Palazon, F	1
Boix, PP	1
Taurbayev, TI	1
Sessolo, M	1
Bolink, HJ	1
Lu, M	1
Lan, Y	1
Xiao, J	1
Song, M	1
Chen, C	1
Huang, Q	1
Cao, Y	1
Ho, CT	1
Qi, B	1
Wang, Q	1
Zhang, W	1
Fang, L	1
Xie, CL	1
Chen, R	1
Yang, S	1
Xia, JM	1
Zhang, GY	1
Chen, CH	1
Yang, XW	1
Domenech-Ximenos, B	1
Garza, MS	1
Prat-González, S	1
Sepúlveda-Martínez, Á	1
Crispi, F	1
Perea, RJ	1
Garcia-Alvarez, A	1
Sitges, M	1
Kalumpha, M	1
Guyo, U	1
Zinyama, NP	1
Vakira, FM	1
Nyamunda, BC	1
Varga, M	1
Drácz, L	1
Kolbenheyer, E	1
Varga, F	1
Patai, ÁV	1
Solymosi, N	1
Patai, Á	1
Kiss, J	1
Gaál, V	1
Nyul, Z	1
Mosdósi, B	1
Valdez, M	1
Moosavi, L	1
Heidari, A	1
Novakovic-Agopian, T	1
Kornblith, E	1
Abrams, G	1
McQuaid, JR	1
Posecion, L	1
Burciaga, J	1
D'Esposito, M	1
Chen, AJW	1
Samy El Gendy, NM	1
Wesolowska, P	1
Georg, D	1
Lechner, W	1
Kazantsev, P	1
Bokulic, T	1
Tedgren, AC	1
Adolfsson, E	1
Campos, AM	1
Alves, VGL	1
Suming, L	1
Hao, W	1
Ekendahl, D	1
Koniarova, I	1
Bulski, W	1
Chelminski, K	1
Samper, JLA	1
Vinatha, SP	1
Rakshit, S	1
Siri, S	1
Tomsejm, M	1
Tenhunen, M	1
Povall, J	1
Kry, SF	1
Followill, DS	1
Thwaites, DI	1
Izewska, J	1
Kang, JH	1
Yoon, Y	1
Song, J	1
Van de Winckel, A	1
Gauthier, L	1
Chao, CT	1
Lee, YH	1
Li, CM	1
Han, DS	1
Huang, JW	1
Ni, L	1
Güttinger, R	1
Triana, CA	1
Spingler, B	1
Baldridge, KK	1
Patzke, GR	1
Shen, X	1
Wang, B	1
Xie, S	1
Deng, W	1
Wu, D	1
Zhang, Q	1
Voskamp, BJ	1
Peelen, MJCS	1
Ravelli, ACJ	1
van der Lee, R	1
Mol, BWJ	1
Pajkrt, E	1
Ganzevoort, W	1
Kazemier, BM	1
Tibrewala, R	1
Bahroos, E	1
Mehrabian, H	1
Foreman, SC	1
Link, TM	1
Pedoia, V	1
Majumdar, S	1
Jablonski, CL	1
Leonard, C	1
Salo, P	1
Krawetz, RJ	1
Yoon, N	1
Hong, SN	1
Cho, JG	1
Jeong, HK	1
Lee, KH	1
Park, HW	1
Barman, S	1
Konai, MM	1
Samaddar, S	1
Haldar, J	1
Mohamed, HSH	1
Li, CF	1
Hu, ZY	1
Deng, Z	1
Chen, LH	1
Su, BL	1
Chu, K	1
Liu, YP	1
Li, YB	1
Zhang, H	1
Xu, C	1
Zou, Z	1
Wu, Z	1
Xia, Y	1
Zhao, P	1
Wang, HT	1
de Biase, S	1
Pellitteri, G	1
Gigli, GL	1
Valente, M	1
Salem, M	1
Sallam, AM	1
Abdel-Aleem, E	1
El-Mesallamy, HO	1
Yin, T	1
Kuo, SC	1
Chang, YY	1
Chen, YT	1
Wang, KK	1
Carvalho, DS	1
de Almeida, AA	1
Borges, AF	1
Vannucci Campos, D	1
Lam, TKT	1
Cherney, DZI	1
Carnovale, C	1
Dassano, A	1
Mosini, G	1
Mazhar, F	1
D'Addio, F	1
Pozzi, M	1
Radice, S	1
Fiorina, P	1
Clementi, E	1
Tabur, S	1
Oğuz, E	1
Sabuncu, T	1
Korkmaz, H	1
Çelik, H	1
Rubio-Guerra, AF	3
Vargas-Robles, H	2
Vargas-Ayala, G	3
Rodriguez-Lopez, L	3
Escalante-Acosta, BA	2
Toto, RD	1
Tian, M	1
Fakouhi, K	1
Champion, A	2
Bacher, P	1
Chen, J	1
Cha-Molstad, H	1
Szabo, A	1
Shalev, A	1
Cooper-DeHoff, RM	1
Handberg, EM	1
Mancia, G	1
Zhou, Q	1
Legler, UF	1
Pepine, CJ	1
Kim, Y	1
Park, K	1
Kang, W	1
Ruggenenti, P	5
Fassi, A	2
Ilieva, A	1
Iliev, IP	3
Chiurchiu, C	1
Rubis, N	3
Gherardi, G	2
Ene-Iordache, B	4
Gaspari, F	3
Perna, A	4
Cravedi, P	1
Bossi, A	3
Trevisan, R	3
Motterlini, N	2
Remuzzi, G	5
Castro-Serna, D	1
Porrini, E	1
Ilieva, AP	2
Dodesini, AR	2
Sampietro, G	1
Capitoni, E	1
Bernadet-Monrozies, P	1
Rostaing, L	1
Kamar, N	1
Durand, D	1
Holzgreve, H	1
Nakov, R	1
Beck, K	1
Janka, HU	1
Lopatin, IuM	1
Kirakozov, DA	1
Statsenko, ME	1
Ruilope, LM	3
Usan, L	1
Segura, J	1
Bakris, GL	4
Arceo-Navarro, A	1
Lozano-Nuevo, JJ	1
Gomez-Harper, CT	1
Bruno, S	1
Brusegan, V	1
Arnoldi, F	1
Ganeva, M	2
Logan, A	1
Gurevich, MA	1
Reynolds, NA	1
Wagstaff, AJ	1
Keam, SJ	1
Henstridge, DC	1
Kingwell, BA	1
Formosa, MF	1
Drew, BG	1
McConell, GK	1
Duffy, SJ	1
Nitschmann, S	1
Glassock, RJ	1
Seres, I	1
Fóris, G	1
Varga, Z	1
Kosztáczky, B	1
Kassai, A	1
Balogh, Z	1
Fülöp, P	1
Paragh, G	1
García Donaire, JA	1
Iskenderov, BG	1
Burmistrova, LF	1
Berenshteĭn, NV	1
Lokhina, TV	1
Röjdmark, S	2
Andersson, DE	2
Ting, HH	1
Timimi, FK	1
Boles, KS	1
Creager, SJ	1
Ganz, P	1
Creager, MA	2
Williams, SB	1
Cusco, JA	1
Roddy, MA	1
Johnstone, MT	1
Schneider, M	1
Lerch, M	1
Papiri, M	1
Buechel, P	1
Boehlen, L	1
Shaw, S	1
Risen, W	1
Weidmann, P	2
Malaisse, WJ	1
Lebrun, P	1
Pirotte, B	1
Van Poelje, PD	1
Viñambres, C	1
Villanueva-Peñacarrillo, ML	1
Valverde, I	1
Gäbel, J	1
Rorsman, P	1
Mangrum, A	1
Copley, JB	1
Vicknair, N	1
Sadler, R	2
Yoo, HJ	1
Kozaki, K	1
Akishita, M	1
Watanabe, M	1
Eto, M	1
Nagano, K	1
Sudo, N	1
Hashimoto, M	1
Kim, S	1
Yoshizumi, M	1
Toba, K	1
Ouchi, Y	1
Streier, K	1
Weir, MR	1
DeQuattro, V	1
McMahon, FG	1
Forman, LM	1
Simmons, DA	1
Diamond, RH	1
de la Sierra, A	1
Moreno, E	1
Fernández, R	2
Garrido, J	3
de la Figuera, M	1
de la Cámara, AG	1
Coca, A	1
Luque-Otero, M	1
Guelpa, G	1
Puig, JG	1
Rodríguez-Pérez, JC	1
Redon, J	1
Faller, J	1
Hess, B	1
Goicolea, I	1
Fernández González, R	1
Piniés, J	1
Martínez, JM	1
Armenteros, S	1
Moreno Carretero, E	1
Lyngsøe, J	2
Sørensen, M	1
Sjøstrand, H	2
Sengeløv, H	2
Thrane, MT	1
Holst, J	1
Barnhill, BW	1
Busch Sørensen, M	1
Tiefenthal Thrane, M	1
Juul Holst, J	1
Ferrier, C	1
Ferrari, P	1
Keller, U	1
Beretta-Piccoli, C	1
Riesen, WF	1
Chellingsworth, MC	1
Kendall, MJ	1
Wright, AD	1
Singh, BM	1
Pasi, J	1
Cruickshank, JK	1
Anderson, NM	1
Wadsworth, J	1
Young, SM	1
Jepson, E	1
Peer, G	1
Korzets, A	1
Levtov, O	1